Kaynak: MarketBeat
Haber Ajansı
Hisse Senedi
Orta Önem
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.
İlgili Semboller
1
S
SNDX
SNDX
Kaynak: MarketBeat
Kaynağı Ziyaret Et